Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2018-12-03 Regulatory Filings
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
Becoming a substantial holder 5 pages 295.9KB
Regulatory Filings
2018-12-03 English
Change in substantial holding 3 pages 187.1KB
Regulatory Filings
2018-11-29 English
Appendix 3B 12 pages 175.6KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements related to these securities. It details the class and number of securities issued, issue price, purpose, and compliance with ASX rules, including placement capacity calculations under rules 7.1 and 7.1A. The document is regulatory in nature, focused on capital raising and securities issuance, not a financial report or earnings release. It is not a full financial report but an announcement of a capital/financing event. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2018-11-29 English
Change of Director's Interest Notice - MB 3 pages 158.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a company director, including number of shares acquired, disposed, and held after the change. The document is a formal notification of insider share transactions by a director, consistent with regulatory requirements for disclosure of personal share dealings by company directors. There is no financial performance data, earnings information, or management discussion. The content matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is about 4935 characters, which is typical for such notices. Therefore, the correct classification is DIRS.
2018-11-29 English
Change of Director's Interest Notice - GK 3 pages 163.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares and options held before and after the change, nature of the change, and dates. This is a clear report of personal share transactions by a company director. The document length is 4282 characters, which is consistent with a detailed director's dealing notice. There is no indication that this is a full financial report, audit, or other type of filing. Therefore, the document fits the definition of Director's Dealing (DIRS).
2018-11-29 English
Opthea Chairman Address to the 2018 AGM 4 pages 159.6KB
AGM Information Classification · 100% confidence The document is titled 'Opthea Chairman’s Address to the 2018 AGM' and is dated 29 November 2018. It is a speech given by the Chairman at the Annual General Meeting (AGM) of Opthea Limited. The content includes updates on the company's progress over the past 12 months, clinical trial developments, financial positioning, and future outlook. It is clearly a presentation or address made during the AGM rather than a formal annual report or financial statement. The document length is 14,332 characters, which is consistent with a detailed AGM address. There is no indication that this is a full Annual Report (10-K) or an Earnings Release (ER). It is not a proxy statement, voting results, or other regulatory filing. Therefore, the most appropriate classification is AGM Information (AGM-R).
2018-11-28 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.